PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.53%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-21.01%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.76%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-10.76%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
0.96%
D&A growth while TRAW reduces D&A. John Neff would investigate differences.
10.97%
EBITDA growth below 50% of TRAW's 49.77%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
10.76%
Operating income growth below 50% of TRAW's 49.83%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
104.37%
Similar other expenses growth to TRAW's 120.06%. Walter Schloss would investigate industry patterns.
11.35%
Pre-tax income growth below 50% of TRAW's 53.14%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
305.13%
Tax expense change of 305.13% while TRAW maintains burden. Bruce Berkowitz would investigate strategy.
11.35%
Net income growth below 50% of TRAW's 53.14%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
31.03%
EPS growth 50-75% of TRAW's 53.59%. Martin Whitman would scrutinize operations.
31.72%
Diluted EPS growth 50-75% of TRAW's 53.59%. Martin Whitman would scrutinize operations.
29.31%
Share count reduction below 50% of TRAW's 0.99%. Michael Burry would check for concerns.
29.44%
Diluted share reduction below 50% of TRAW's 0.99%. Michael Burry would check for concerns.